Clinical-stage biopharmaceutical company Inventiva released preliminary financial results for fiscal year 2025, demonstrating a substantially fortified liquidity position following its U.S. public offering. The company reported cash and cash equivalents totaling €99.3 million alongside €131.6 million in short-term deposits, providing a combined liquid asset base of €230.9 million. The capital raise generated $172.5 million, complemented by structured financing arrangements that enhance the company's financial flexibility.
Operational metrics reflect the company's focus on its pipeline development, with R&D expenses of €86.9 million concentrated on advancing lanifibranor, its lead candidate for metabolic dysfunction-associated fatty liver disease (MASH) treatment. For the 2025 fiscal year, the company generated €4.5 million in revenues while consuming €104.6 million in operating activities. The elevated cash burn reflects typical spending patterns for clinical-stage biopharmaceutical firms advancing late-stage development programs.
Based on current burn rates and available resources, Inventiva projects its cash runway extending through mid-Q1 2027, with the potential to extend operations through mid-Q3 2027 should all Tranche 3 warrants from the financing structure be fully exercised. The extended runway provides the company with sufficient capital to progress its clinical development objectives and advance toward key inflection points in its MASH program.